Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ponatinib hydrochloride by Takeda Pharmaceutical for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Ponatinib hydrochloride is under clinical development by Takeda Pharmaceutical and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute...
Ponatinib hydrochloride by Takeda Pharmaceutical for Non-Small Cell Lung Cancer: Likelihood of Approval
Ponatinib hydrochloride is under clinical development by Takeda Pharmaceutical and currently in Phase II for Non-Small Cell Lung Cancer. According...
Ponatinib hydrochloride by Takeda Pharmaceutical for Biliary Tumor: Likelihood of Approval
Ponatinib hydrochloride is under clinical development by Takeda Pharmaceutical and currently in Phase II for Biliary Tumor. According to GlobalData,...
Ponatinib hydrochloride by Takeda Pharmaceutical for Central Nervous System (CNS) Tumor: Likelihood of Approval
Ponatinib hydrochloride is under clinical development by Takeda Pharmaceutical and currently in Phase II for Central Nervous System (CNS) Tumor....
Ponatinib hydrochloride by Takeda Pharmaceutical for Lymphoma: Likelihood of Approval
Ponatinib hydrochloride is under clinical development by Takeda Pharmaceutical and currently in Phase II for Lymphoma. According to GlobalData, Phase...